New research sets the stage for clinicians to potentially one day use levels of a pancreatic cancer patient’s PHLPP1 and PKC enzymes as a prognostic, and for researchers to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC as a means to treat the disease.
